These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 36570687)

  • 1. Dalbavancin in clinical practice in Spain: a 2 year retrospective study.
    Morata L; Aguado JM; Salavert M; Pasquau J; Míguez E; Muñoz P; Rosselló I; Almirante B
    JAC Antimicrob Resist; 2022 Dec; 4(6):dlac120. PubMed ID: 36570687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. REDS study: Retrospective effectiveness study of dalbavancin and other standard of care of the same IV antibiotic class in patients with ABSSSI.
    Papavramidis T; Gentile I; Cattelan AM; Magnasco L; Viale P; Francisci D; Kofteridis DP; Tiseo G; Giamarellos-Bourboulis EJ; Lagi F; Pinna SM; D'Amico F; La Ferla L; Panagopoulos P; Gattuso G; Sipsas NV; Ruggieri A; Cattaneo A; Corio L; Comandini A; Mascagni P; Bassetti M
    Int J Antimicrob Agents; 2023 Apr; 61(4):106746. PubMed ID: 36758778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dalbavancin real-life utilization among diabetic patients suffering from infections in Italy and Spain: The DALBADIA retrospective cohort study.
    Morata Ruiz L; Ruggieri A; Falcone M; Pasquau Liaño J; Gentile I; Salavert Lletí M; Moreno Núñez L; Cascio A; Tascini C; Loeches Yagüe M; De Rosa FG; Ori A; Comandini A; Cattaneo A; Grossi PA;
    J Glob Antimicrob Resist; 2024 Mar; 36():200-209. PubMed ID: 38211660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Data Regarding Dalbavancin Use before and during the COVID-19 Pandemic-A Single-Center Retrospective Study.
    Ioannou P; Wolff N; Mathioudaki A; Spanias C; Spernovasilis N; Kofteridis DP
    Antibiotics (Basel); 2023 Jul; 12(7):. PubMed ID: 37508301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dalbavancin in the treatment of different gram-positive infections: a real-life experience.
    Bouza E; Valerio M; Soriano A; Morata L; Carus EG; Rodríguez-González C; Hidalgo-Tenorio MC; Plata A; Muñoz P; Vena A;
    Int J Antimicrob Agents; 2018 Apr; 51(4):571-577. PubMed ID: 29180276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on activity of dalbavancin and comparators against clinical isolates of Gram-positive pathogens from Europe and Russia (2017-2018), and on clonal distribution of MRSA.
    Riccobono E; Giani T; Baldi G; Arcangeli S; Antonelli A; Tellone V; Del Vecchio A; De Joannon AC; Rossolini GM
    Int J Antimicrob Agents; 2022 Feb; 59(2):106503. PubMed ID: 34929289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost analysis of disease including treatment with dalbavancin in a Spanish hospital: ECODAL ANALYSIS.
    Valerio M; Veintimilla C; Rodríguez C; de la Villa S; Sánchez-Somolinos M; Cerezales M; Crespo C; Rodríguez S; Adán I; Chamorro E; Rosselló I; Muñoz P
    J Med Econ; 2023; 26(1):463-472. PubMed ID: 36950932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety of dalbavancin in France: a prospective, multicentre cohort study.
    Courjon J; Senneville E; Illes HG; Pavese P; Boutoille D; Daoud FC; Dunkel N; Tattevin P
    Int J Antimicrob Agents; 2023 Oct; 62(4):106945. PubMed ID: 37543122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dalbavancin Efficacy and Impact on Hospital Length-of-Stay and Treatment Costs in Different Gram-Positive Bacterial Infections.
    Poliseno M; Bavaro DF; Brindicci G; Luzzi G; Carretta DM; Spinarelli A; Messina R; Miolla MP; Achille TI; Dibartolomeo MR; Dell'Aera M; Saracino A; Angarano G; Favale S; D'Agostino C; Moretti B; Signorelli F; Taglietti C; Carbonara S
    Clin Drug Investig; 2021 May; 41(5):437-448. PubMed ID: 33884583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dalbavancin Use in Vulnerable Patients Receiving Outpatient Parenteral Antibiotic Therapy for Invasive Gram-Positive Infections.
    Bork JT; Heil EL; Berry S; Lopes E; Davé R; Gilliam BL; Amoroso A
    Infect Dis Ther; 2019 Jun; 8(2):171-184. PubMed ID: 31054088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness, safety and cost analysis of dalbavancin in clinical practice.
    Arrieta-Loitegui M; Caro-Teller JM; Ortiz-Pérez S; López-Medrano F; San Juan-Garrido R; Ferrari-Piquero JM
    Eur J Hosp Pharm; 2022 Jan; 29(1):55-58. PubMed ID: 33020060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study).
    Bai F; Aldieri C; Cattelan A; Raumer F; Di Meco E; Moioli MC; Tordato F; Morelli P; Borghi F; Rizzi M; Van Hauwermeiren E; Castelli F; Migliorino G; Menzaghi B; Rizzardini G; Saracino A; Cascio A; Puoti M; d'Arminio Monforte A; Marchetti G
    Expert Rev Anti Infect Ther; 2020 Dec; 18(12):1271-1279. PubMed ID: 32797758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Off-label use of dalbavancin in children: a case series.
    Gamell A; Velasco-Arnaiz E; López-Ramos MG; Ríos-Barnés M; Simó-Nebot S; Fumadó V; Noguera-Julián A; Fortuny C
    J Antimicrob Chemother; 2024 Jul; ():. PubMed ID: 38958260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Budget Impact Analysis of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections in Three European Countries.
    Marcellusi A; Bini C; Andreoni M; Sarmati L; Espin J; Horcajada JP; Czypionka T; Andretta D; Sciattella P; Favato G; Mennini FS
    Clin Drug Investig; 2020 Apr; 40(4):305-318. PubMed ID: 32034687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Use of Dalbavancin for Treatment of Soft Tissue and Bone Infection in Children: Safe, Effective and Hospital-Time Sparing.
    Caselli D; Mariani M; Colomba C; Ferrecchi C; Cafagno C; Trotta D; Carloni I; Dibello D; Castagnola E; Aricò M
    Children (Basel); 2024 Jan; 11(1):. PubMed ID: 38255391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes in Patients with Staphylococcus aureus Bacteremia Treated with Dalbavancin in Clinical Trials.
    Gonzalez PL; Rappo U; Akinapelli K; McGregor JS; Puttagunta S; Dunne MW
    Infect Dis Ther; 2022 Feb; 11(1):423-434. PubMed ID: 34905144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dalbavancin in the treatment of acute bacterial skin and skin structure and other infections: a safety evaluation.
    Righi E; Visentin A; Meroi M; Carrara E; Tacconelli E
    Expert Opin Drug Saf; 2022 Sep; 21(9):1171-1181. PubMed ID: 36093622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of osteoarticular, cardiovascular, intravascular-catheter-related and other complicated infections with dalbavancin and oritavancin: A systematic review.
    Thomas G; Henao-Martínez AF; Franco-Paredes C; Chastain DB
    Int J Antimicrob Agents; 2020 Sep; 56(3):106069. PubMed ID: 32603683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Multicentre, Prospective, and Retrospective Registry to Characterize the Use, Effectiveness, and Safety of Dalbavancin in German Clinical Practice.
    Hanses F; Dolff S; Trauth J; Seimetz M; Hagel S
    Antibiotics (Basel); 2022 Apr; 11(5):. PubMed ID: 35625206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost analysis of dalbavancin versus standard of care for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in two Italian hospitals.
    Bai F; Mazzitelli M; Silvola S; Raumer F; Restelli U; Croce D; Marchetti G; Cattelan AM
    JAC Antimicrob Resist; 2023 Apr; 5(2):dlad044. PubMed ID: 37090914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.